Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses-Reference-Cited by-同舟云学术

Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses

Published:2022-10-26 Issue:5 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Lin Yi-Chan J.¹,Evans David H.¹^ORCID,Robbins Ninette F.²,Orjuela Guillermo³,Hu Queenie⁴,Samson Reuben⁴⁵,Abe Kento T.⁴⁵,Rathod Bhavisha⁴,Colwill Karen⁴,Gingras Anne-Claude⁴⁵,Tuite Ashleigh⁶,Yi Qi-Long⁷⁸,O’Brien Sheila F.⁷⁸^ORCID,Drews Steven J.⁹¹⁰^ORCID

Affiliation:

1. Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Alberta, Canada

2. Scientific Affairs, Abbott Transfusion Medicine, Chicago, Illinois, USA

3. Scientific Affairs, Abbott Transfusion Medicine, Bogotá, Colombia

4. Lunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health, Toronto, Ontario, Canada

5. Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada

6. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

7. Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario, Canada

8. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada

9. Canadian Blood Services, Microbiology, Edmonton, Alberta, Canada

10. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada

Abstract

The United States Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of COVID-19 convalescent plasma (CCP) to treat hospitalized patients with COVID-19 in August 2020. However, by 4 February 2021, the FDA had revised the convalescent plasma EUA.

Funder

Alberta Innovates

Alberta Innovates - Health Solutions

Gouvernement du Canada | Canadian Institutes of Health Research

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.02811-22

Reference37 articles.

1. National Institutes of Health. 16 December 2021. Coronavirus disease 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/. Accessed 16 August 2022.

2. A trend of dropping anti‐SARS‐CoV‐2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors

3. A simple protein-based surrogate neutralization assay for SARS-CoV-2

4. Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

5. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases;Heliyon;2024-05

2. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco;Scientific Reports;2024-04-03

3. Multicentric evaluation of sensitivity of eight commercial anti-SARS-CoV-2 antibody assays and their correlation to virus neutralization titers in seropositive subjects;Scientific Reports;2024-01-16

4. Evaluation of commercial assays for the assessment of SARS-CoV-2 antibody response in hemodialysis patients;Clinical Biochemistry;2023-11

5. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021;Microbiology Spectrum;2023-08-17